Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress

Hirano, Shin-ichi; Ichikawa, Yusuke; Sato, Bunpei; Yamamoto, Haru; Takefuji, Yoshiyasu; Satoh, Fumitake

doi:10.3390/ijms22052549

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessReview

Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress

¹,

¹,

²,

^3,*

and

Fumitake Satoh

Department of Research and Development, MiZ Company Limited, 2-19-15 Ofuna, Kamakura, Kanagawa 247-0056, Japan

Department of Molecular & Cell Biology, University of California, 3060 Valley Life Sciences Bldg #3140, Berkeley, CA 94720-3140, USA

Faculty of Environment and Information Studies, Keio University, 5322 Endo, Fujisawa 252-0882, Japan

Author to whom correspondence should be addressed.

Academic Editor: Sara Franceschelli

Int. J. Mol. Sci. 2021, 22(5), 2549; https://doi.org/10.3390/ijms22052549

Received: 26 January 2021 / Revised: 26 February 2021 / Accepted: 1 March 2021 / Published: 4 March 2021

(This article belongs to the Special Issue Biological Role of Oxidative Stress in Inflammatory Diseases)

View Full-Text Download PDF

Browse Figure

Citation Export

Abstract

Mitochondria are the largest source of reactive oxygen species (ROS) and are intracellular organelles that produce large amounts of the most potent hydroxyl radical (·OH). Molecular hydrogen (H₂) can selectively eliminate ·OH generated inside of the mitochondria. Inflammation is induced by the release of proinflammatory cytokines produced by macrophages and neutrophils. However, an uncontrolled or exaggerated response often occurs, resulting in severe inflammation that can lead to acute or chronic inflammatory diseases. Recent studies have reported that ROS activate NLRP3 inflammasomes, and that this stimulation triggers the production of proinflammatory cytokines. It has been shown in literature that H₂ can be based on the mechanisms that inhibit mitochondrial ROS. However, the ability for H₂ to inhibit NLRP3 inflammasome activation via mitochondrial oxidation is poorly understood. In this review, we hypothesize a possible mechanism by which H₂ inhibits mitochondrial oxidation. Medical applications of H₂ may solve the problem of many chronic inflammation-based diseases, including coronavirus disease 2019 (COVID-19). View Full-Text

Keywords: hydrogen; chronic inflammatory disease; medical application; hydroxyl radical; reactive oxygen species; NLRP3; COVID-19

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Hirano, S.-i.; Ichikawa, Y.; Sato, B.; Yamamoto, H.; Takefuji, Y.; Satoh, F. Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress. Int. J. Mol. Sci. 2021, 22, 2549. https://doi.org/10.3390/ijms22052549

AMA Style

Hirano S-i, Ichikawa Y, Sato B, Yamamoto H, Takefuji Y, Satoh F. Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress. International Journal of Molecular Sciences. 2021; 22(5):2549. https://doi.org/10.3390/ijms22052549

Chicago/Turabian Style

Hirano, Shin-ichi, Yusuke Ichikawa, Bunpei Sato, Haru Yamamoto, Yoshiyasu Takefuji, and Fumitake Satoh. 2021. "Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress" International Journal of Molecular Sciences 22, no. 5: 2549. https://doi.org/10.3390/ijms22052549

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Access Map by Country/Region

Author Biographies

Shin-ichi Hirano

1:Shin-ichi Hirano, Director and Chief Scientific Officer, MiZ Company Limited. 2: 1969 - 1973: Research student, Faculty of Veterinary Medicine, Kagoshima University; 1988 - 1991, Graduate research student, Faculty of Veterinary medicine, Nippon Veterinary and Life Science University. Veterinarian (1973), Ph.D. in Veterinary medicine (Veterinary pharmacology, 1991). 3: 1973 - 1998: Senior researcher, Mercian Corporation. 1998 - 2012: Research manager and Director, Mercian Cleantec Corporation. 2012 -: Director and Chief Scientific Officer, MiZ Company Limited. 4: Pharmacology, Toxicology, Hydrogen medicine. 5: Academic councilor of Japanese Pharmacological Society (1994 -). No. of published papers: 76.

Yusuke Ichikawa

1: Yusuke Ichikawa, Research and Development Department, MiZ Company Limited. 2: 1996-2000: Undergraduate student, Department of Science and Engineering, Faculty of Applied Chemistry, Chuo University; 2000 - 2002, Graduate school student (Master course), Faculty of Medical Science, School of Medicine, Keio University, 2002 - 2006: Graduate school student (Doctor course), School of Science, Department of Chemistry, Nagoya University 3: 2006 – 2008: Researcher, Asahi Glass Corporation. 2008 – 2009: Promega Corporation. 2009 – 2016: Patent Engineer, Tani-Abe, P.C. Department of Chemistry. 4: Organic Chemistry, Protein Chemistry, Cell Biology, Hydrogen medicine. 5: nothing in particular.

Bunpei Sato

1: Bunpei Sato, Executive Director, MiZ Company Limited. 2: 1993-1997: Student, Faculty of Literature, Keio University. 3: 2001- : Research and Development Department, MiZ Company Limited. 4: Hydrogen medicine. 5: nothing in particular.

Yoshiyasu Takefuji

Graduated from Electrical Eng. of Keio Univ. (1978), MS (1980), Ph.D. (1983) respectively. Assistant Professor: Univ. of South Florida (1983-1985), Associate Professor: Univ. of South Carolina (1985-1988), Associate Professor: Case Western Reserve Univ. (1988-1996: tenured in 1992), Professor: Keio University(1992-present). Research: cyber-security, neural computing, energy harvesting, IoT, AI. He authors 40 books and more than 600 articles with supervising more than 40 Ph.D. students. He published 208 eLetters and 1 report in Science and 1 correspondence in Nature.

Fumitake Satoh

1: Fumitake Satoh, Representative Director, MiZ Company Limited. 2: 1966-1970: Student, Faculty of Arts, Nippon University. 3: 1991-: Research and Development Department, MiZ Company Limited. 4: Hydrogen medicine. 5: nothing in particular.

Article Menu

Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Author Biographies

Further Information

Guidelines

MDPI Initiatives

Follow MDPI